ABBV RSI Chart
Last 7 days
-0.8%
Last 30 days
-5.5%
Last 90 days
-8.2%
Trailing 12 Months
9.2%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 54.4B | 0 | 0 | 0 |
2023 | 56.7B | 56.0B | 55.1B | 54.3B |
2022 | 56.7B | 57.3B | 57.8B | 58.1B |
2021 | 50.2B | 53.7B | 55.2B | 56.2B |
2020 | 34.1B | 36.2B | 40.6B | 45.8B |
2019 | 32.6B | 32.6B | 32.9B | 33.3B |
2018 | 29.6B | 30.9B | 32.2B | 32.8B |
2017 | 26.2B | 26.7B | 27.3B | 28.2B |
2016 | 23.8B | 24.8B | 25.2B | 25.6B |
2015 | 20.4B | 21.0B | 21.9B | 22.9B |
2014 | 19.0B | 19.3B | 19.6B | 20.0B |
2013 | 18.5B | 18.7B | 18.9B | 18.8B |
2012 | 17.7B | 17.9B | 18.1B | 18.4B |
2011 | 0 | 0 | 0 | 17.4B |
2010 | 0 | 0 | 0 | 15.6B |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index
Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.
Returns of $10,000 invested in:
Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022
Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 03, 2024 | davis jennifer l. | acquired | - | - | 1,322 | - |
May 03, 2024 | waddell frederick h | acquired | - | - | 1,322 | - |
May 03, 2024 | freyman thomas c | acquired | - | - | 1,322 | - |
May 03, 2024 | tilton glenn f | acquired | - | - | 1,322 | - |
May 03, 2024 | rapp edward j | acquired | - | - | 1,322 | - |
May 03, 2024 | meyer melody b | acquired | - | - | 1,322 | - |
May 03, 2024 | austin roxanne s | acquired | - | - | 1,322 | - |
May 03, 2024 | quaggin susan e | acquired | - | - | 1,322 | - |
May 03, 2024 | alpern robert j | acquired | - | - | 1,322 | - |
May 03, 2024 | roberts rebecca b | acquired | - | - | 1,322 | - |
Which funds bought or sold ABBV recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 07, 2024 | GW HENSSLER & ASSOCIATES LTD | reduced | -1.62 | 4,034,730 | 29,886,700 | 1.75% |
May 07, 2024 | OBERMEYER WOOD INVESTMENT COUNSEL, LLLP | added | 72.78 | 1,670,070 | 3,291,120 | 0.19% |
May 07, 2024 | Mondrian Investment Partners LTD | reduced | -5.36 | 16,802,400 | 166,786,000 | 2.29% |
May 07, 2024 | THOROUGHBRED FINANCIAL SERVICES, LLC | reduced | -2.23 | 613,000 | 4,736,000 | 0.46% |
May 07, 2024 | Strategic Financial Services, Inc, | reduced | -0.78 | 104,904 | 737,801 | 0.05% |
May 07, 2024 | NTV Asset Management LLC | added | 0.99 | 1,094,610 | 6,956,040 | 1.06% |
May 07, 2024 | OPPENHEIMER & CO INC | reduced | -3.15 | 3,321,700 | 27,381,100 | 0.45% |
May 07, 2024 | KCM INVESTMENT ADVISORS LLC | added | 0.14 | 2,174,690 | 14,484,300 | 0.54% |
May 07, 2024 | Smithfield Trust Co | added | 0.51 | 933,000 | 6,035,000 | 0.32% |
May 07, 2024 | Cove Street Capital, LLC | unchanged | - | 27,130 | 182,100 | 0.06% |
Unveiling AbbVie Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to AbbVie Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 358.5B | 85.6B | 9.32 | 4.19 | ||||
MRK | 328.0B | 61.4B | 142.26 | 5.34 | ||||
AMGN | 164.9B | 29.5B | 43.82 | 5.58 | ||||
PFE | 160.3B | 57.8B | 127.84 | 2.77 | ||||
GILD | 80.9B | 27.4B | 166.89 | 2.95 | ||||
TEVA | 17.8B | 16.0B | -36.05 | 1.11 | ||||
MID-CAP | ||||||||
PRGO | 4.2B | 4.6B | -550.77 | 0.93 | ||||
ALKS | 4.1B | 1.7B | 9.39 | 2.36 | ||||
BHC | 2.6B | 9.0B | -5.66 | 0.29 | ||||
AMPH | 2.0B | 644.4M | 14.76 | 3.15 | ||||
SMALL-CAP | ||||||||
TLRY | 1.5B | 743.2M | -4.27 | 2.02 | ||||
TXMD | 23.3M | 1.3M | -2.27 | 17.89 | ||||
ACRX | 17.5M | - | -0.95 | 0.22 | ||||
AGRX | 2.7M | 19.6M | -0.19 | 0.14 | ||||
ACOR | 1.1M | 117.6M | 0 | 0.01 |
AbbVie Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -13.9% | 12,310 | 14,301 | 13,927 | 13,865 | 12,225 | 15,121 | 14,812 | 14,583 | 13,538 | 14,886 | 14,342 | 13,959 | 13,010 | 13,858 | 12,902 | 10,425 | 8,619 | 8,704 | 8,479 | 8,255 | 7,828 |
Costs and Expenses | -14.4% | 9,512 | 11,106 | 11,646 | 9,352 | 9,457 | 9,619 | 10,209 | 11,288 | 8,821 | 9,812 | 10,036 | 9,518 | 8,907 | 10,105 | 9,647 | 9,673 | 5,016 | 4,748 | 5,862 | 4,855 | 4,818 |
S&GA Expenses | 3.8% | 3,315 | 3,193 | 3,372 | 3,268 | 3,039 | 3,417 | 3,304 | 5,412 | 3,127 | 3,260 | 3,083 | 3,164 | 2,842 | 3,231 | 2,846 | 3,527 | 1,695 | 1,951 | 1,657 | 1,654 | 1,680 |
EBITDA Margin | 13.3% | 0.20* | 0.17* | 0.21* | 0.25* | 0.22* | 0.29* | 0.32* | 0.31* | 0.31* | 0.29* | 0.19* | 0.18* | - | - | - | - | - | - | - | - | - |
Income Taxes | -1.3% | 383 | 388 | 172 | 583 | 234 | 493 | 448 | 255 | 436 | 226 | 508 | 394 | 312 | -1,545 | 187 | 46.00 | 88.00 | 273 | 117 | 66.00 | 88.00 |
Earnings Before Taxes | 44.8% | 1,755 | 1,212 | 1,953 | 2,610 | 475 | 2,965 | 4,400 | 1,183 | 4,929 | 4,271 | 3,688 | 1,163 | 3,867 | -1,507 | 2,500 | -693 | 3,098 | 3,074 | 2,001 | 807 | 2,544 |
EBT Margin | 20.3% | 0.14* | 0.12* | 0.15* | 0.19* | 0.16* | 0.23* | 0.26* | 0.25* | 0.25* | 0.23* | 0.13* | 0.11* | - | - | - | - | - | - | - | - | - |
Net Income | 65.3% | 1,359 | 822 | 1,778 | 2,024 | 239 | 2,473 | 3,949 | 924 | 4,490 | 4,044 | 3,179 | 766 | 3,553 | 36.00 | 2,308 | -738 | 3,010 | 2,801 | 1,884 | 741 | 2,456 |
Net Income Margin | 22.8% | 0.11* | 0.09* | 0.12* | 0.16* | 0.13* | 0.20* | 0.23* | 0.22* | 0.22* | 0.21* | 0.14* | 0.12* | - | - | - | - | - | - | - | - | - |
Free Cashflow | -15.4% | 3,847 | 4,548 | 7,355 | 6,141 | 4,018 | 7,215 | 7,425 | 4,862 | 4,746 | 4,888 | 7,718 | 4,695 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 10.5% | 148,874 | 134,711 | 136,221 | 135,367 | 134,544 | 138,805 | 141,325 | 143,186 | 143,211 | 146,529 | 148,858 | 147,972 | 150,501 | 150,565 | 149,621 | 149,530 | 91,199 | 89,115 | 59,441 | 57,142 | 56,769 |
Current Assets | 17.8% | 38,871 | 33,002 | 33,224 | 28,852 | 26,488 | 28,463 | 30,364 | 29,100 | 26,509 | 27,928 | 28,957 | 25,999 | 26,569 | 24,173 | 23,009 | 21,256 | 51,758 | 49,519 | 20,166 | 15,100 | 14,413 |
Cash Equivalents | 41.0% | 18,067 | 12,814 | 13,287 | 8,759 | 6,711 | 9,201 | 11,832 | 8,521 | 6,098 | 9,746 | 12,182 | 8,546 | 9,755 | 8,449 | 7,890 | 6,017 | 41,142 | 39,924 | 10,648 | 5,172 | 4,897 |
Inventory | 3.6% | 4,245 | 4,099 | 3,981 | 4,055 | 3,833 | 3,579 | 3,172 | 3,396 | 3,483 | 3,128 | 3,094 | 3,386 | 3,272 | 3,310 | 3,474 | 4,059 | 1,844 | 1,813 | 1,929 | 1,895 | 1,702 |
Net PPE | -0.2% | 4,980 | 4,989 | 4,934 | 4,943 | 4,931 | 4,935 | 4,893 | 4,958 | 5,075 | 5,110 | 5,130 | 5,161 | 5,193 | 5,248 | 4,986 | 4,908 | 2,961 | 2,962 | 2,894 | 2,879 | 2,860 |
Goodwill | 3.5% | 33,426 | 32,293 | 32,091 | 32,224 | 32,220 | 32,156 | 31,726 | 32,028 | 32,298 | 32,379 | 32,296 | 32,398 | 32,349 | 33,124 | 42,801 | 42,669 | 15,561 | 15,604 | 15,537 | 15,642 | 15,606 |
Current Liabilities | 9.7% | 41,522 | 37,841 | 34,773 | 32,239 | 27,590 | 29,538 | 32,712 | 34,473 | 32,521 | 35,194 | 28,533 | 28,684 | 31,951 | 28,661 | 24,181 | 24,646 | 16,471 | 15,585 | 17,493 | 16,941 | 13,904 |
Short Term Borrowings | - | 3.00 | - | 2.00 | - | 1.00 | 1.00 | 10.00 | 17.00 | 12.00 | 14.00 | 16.00 | 17.00 | 9.00 | 34.00 | 54.00 | 64.00 | 6.00 | - | - | 306 | 499 |
Long Term Debt | 22.2% | 63,805 | 52,194 | 55,631 | 55,812 | 59,292 | 59,135 | 60,399 | 61,002 | 63,522 | 64,189 | 74,049 | 74,237 | 74,183 | 77,554 | 82,282 | 82,061 | 63,284 | 62,975 | 33,126 | 31,619 | 35,066 |
Shareholder's Equity | -22.3% | 8,047 | 10,360 | 12,094 | 12,898 | 13,303 | 17,254 | 16,027 | 14,688 | 16,314 | 15,436 | 13,577 | 12,594 | 13,733 | 13,097 | 15,289 | 14,732 | - | - | - | - | - |
Retained Earnings | -138.4% | -2,384 | -1,000 | 933 | 1,789 | 2,393 | 4,784 | 4,953 | 3,516 | 5,103 | 3,127 | 1,600 | 740 | 2,292 | 1,055 | 3,335 | 3,130 | 5,973 | 4,717 | 3,673 | 3,384 | 4,234 |
Additional Paid-In Capital | 2.4% | 20,656 | 20,180 | 20,021 | 19,839 | 19,619 | 19,245 | 19,056 | 18,906 | 18,731 | 18,305 | 18,108 | 17,936 | 17,712 | 17,384 | 17,148 | 16,953 | 15,401 | 15,193 | 15,112 | 15,028 | 14,940 |
Shares Outstanding | 0.1% | 1,769 | 1,768 | 1,768 | 1,768 | 1,770 | 1,771 | 1,771 | 1,770 | 1,771 | 1,770 | 1,769 | 1,769 | - | - | - | - | - | - | - | - | - |
Minority Interest | 8.1% | 40.00 | 37.00 | 35.00 | 32.00 | 29.00 | 33.00 | 33.00 | 35.00 | 31.00 | 28.00 | 27.00 | 25.00 | 23.00 | 21.00 | 19.00 | 24.00 | - | - | - | - | - |
Float | - | - | - | - | 235,630 | - | - | - | 268,253 | - | - | - | 197,246 | - | - | - | 171,597 | - | - | - | 106,362 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -15.0% | 4,040 | 4,753 | 7,574 | 6,319 | 4,193 | 7,428 | 7,602 | 5,005 | 4,908 | 5,075 | 7,935 | 4,890 | 4,877 | 4,854 | 5,830 | 3,089 | 3,815 | 3,275 | 4,555 | 2,477 | 3,017 |
Share Based Compensation | 178.4% | 348 | 125 | 130 | 179 | 313 | 132 | 126 | 107 | 306 | 129 | 135 | 159 | 269 | 136 | 162 | 236 | 219 | 79.00 | 75.00 | 87.00 | 189 |
Cashflow From Investing | -1098.5% | -9,588 | -800 | -369 | -341 | -499 | -448 | 1,286 | 130 | -1,591 | -1,145 | -615 | -242 | -342 | -627 | -1,149 | -35,652 | -129 | -615 | 1,378 | -140 | -27.00 |
Cashflow From Financing | 343.2% | 10,819 | -4,449 | -2,661 | -3,920 | -6,192 | -9,634 | -5,518 | -2,679 | -6,972 | -6,338 | -3,643 | -5,884 | -3,174 | -3,695 | -2,814 | -2,570 | -2,422 | 26,602 | -441 | -2,070 | -5,383 |
Dividend Payments | 5.6% | 2,772 | 2,626 | 2,627 | 2,625 | 2,661 | 2,506 | 2,504 | 2,507 | 2,526 | 2,314 | 2,315 | 2,310 | 2,322 | 2,101 | 2,100 | 1,752 | 1,763 | 1,595 | 1,591 | 1,592 | 1,588 |
Buy Backs | 44033.3% | 1,324 | 3.00 | 4.00 | 10.00 | 1,955 | 4.00 | 4.00 | 9.00 | 1,470 | 131 | 6.00 | 10.00 | 787 | 296 | 20.00 | 19.00 | 643 | 2.00 | 4.00 | 3.00 | 620 |
Condensed Consolidated Statements of Earnings (Unaudited) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Net revenues | $ 12,310 | $ 12,225 |
Cost of products sold | 4,094 | 3,986 |
Selling, general and administrative | 3,315 | 3,039 |
Research and development | 1,939 | 2,292 |
Acquired IPR&D and milestones | 164 | 150 |
Other operating income | 0 | (10) |
Total operating costs and expenses | 9,512 | 9,457 |
Operating earnings | 2,798 | 2,768 |
Interest expense, net | 453 | 454 |
Net foreign exchange loss | 4 | 35 |
Other expense, net | 586 | 1,804 |
Earnings before income tax expense | 1,755 | 475 |
Income tax expense | 383 | 234 |
Net earnings | 1,372 | 241 |
Net earnings attributable to noncontrolling interest | 3 | 2 |
Net earnings attributable to AbbVie Inc. | $ 1,369 | $ 239 |
Per share data | ||
Basic earnings per share (in dollars per share) | $ 0.77 | $ 0.13 |
Diluted earnings per share (in dollars per share) | $ 0.77 | $ 0.13 |
Weighted-average basic shares outstanding (in shares) | 1,769 | 1,770 |
Weighted-average diluted shares outstanding (in shares) | 1,773 | 1,776 |
Condensed Consolidated Balance Sheets - USD ($) $ in Millions | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets | ||
Cash and equivalents | $ 18,067 | $ 12,814 |
Short-term investments | 2 | 2 |
Accounts receivable, net | 11,949 | 11,155 |
Inventories | 4,245 | 4,099 |
Prepaid expenses and other | 4,608 | 4,932 |
Total current assets | 38,871 | 33,002 |
Investments | 305 | 304 |
Property and equipment, net | 4,980 | 4,989 |
Intangible assets, net | 62,225 | 55,610 |
Goodwill | 33,426 | 32,293 |
Other assets | 9,067 | 8,513 |
Total assets | 148,874 | 134,711 |
Current liabilities | ||
Short-term borrowings | 3 | 0 |
Current portion of long-term debt and finance lease obligations | 10,193 | 7,191 |
Accounts payable and accrued liabilities | 31,326 | 30,650 |
Total current liabilities | 41,522 | 37,841 |
Long-term debt and finance lease obligations | 63,805 | 52,194 |
Deferred income taxes | 2,722 | 1,952 |
Other long-term liabilities | 32,778 | 32,327 |
Commitments and contingencies | ||
Stockholders' equity | ||
Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,829,957,662 shares issued as of March 31, 2024 and 1,823,046,087 as of December 31, 2023 | 18 | 18 |
Common stock held in treasury, at cost, 64,234,512 shares as of March 31, 2024 and 57,105,354 as of December 31, 2023 | (7,829) | (6,533) |
Additional paid-in capital | 20,656 | 20,180 |
Accumulated deficit | (2,384) | (1,000) |
Accumulated other comprehensive loss | (2,454) | (2,305) |
Total stockholders' equity | 8,007 | 10,360 |
Noncontrolling interest | 40 | 37 |
Total equity | 8,047 | 10,397 |
Total liabilities and equity | $ 148,874 | $ 134,711 |
 | Mr. Richard A. Gonzalez |
---|---|
 | abbvie.com |
 | Pharmaceuticals |
 | 50000 |